6/7/2017 1:44:54 PM
Life Sciences Jobs
• Newest Jobs – Last 24 Hours
• California Jobs
• Massachusetts Jobs
• New Jersey Jobs
• Maryland Jobs
• Washington Jobs
View More Jobs
PressureStim is designed to lower high blood pressure by improving elastic compliance of the aorta and other arteries and bioelectric potentials balance management throughout the body.
Santa Monica, CA and Salt Lake City, Utah (PRBUZZ) – Today the team at Leonhardt’s Launchpads announced the launch of a new startup PressureStim that will focus on the development of bioelectric treatments for lowering high blood pressure. The original prototype devices being built and tested have the below listed design features.
The original PressureStim device design has three primary components of blood pressure control therapy:
1. Wireless bioelectric signals for increasing arterial compliance via controlled release of growth factors such as tropoelastin.
2. Wireless bioelectric signals to manage the control of blood pressure between the brain and hormonal glands.
3. Bioelectric signals delivered via the nervous and cardiovascular system to manage total body electrical potentials balance.
The original prototype device is about the size of a quarter.
“When arteries get stiff and hardened the body loses its main natural blood pressure dampening system and high blood pressure sets in. Secondarily the bioelectric current potentials management between the brain, the hormonal glans of the body and arterial walls must be in balance for healthy blood pressure. The PressureStim device is being designed to be the first therapy to address multiple known root causes of hypertension. We look forward to soon be reporting to you initial test results.” states Dr. Leslie Miller, Chief Medical Officer
More than 1 billion people suffer of high blood pressure worldwide. Blood pressure levels have been shown to be positively and continuously related to the risk for stroke and coronary heart disease. In some age groups, the risk of cardiovascular disease doubles for each increment of 20/10 mmHg of blood pressure, starting as low as 115/75 mmHg. In addition to coronary heart diseases and stroke, complications of raised blood pressure include heart failure, peripheral vascular disease, renal impairment, retinal hemorrhage and visual impairment. Treating systolic blood pressure and diastolic blood pressure until they are less than 140/90 mmHg is associated with a reduction in cardiovascular complications.
It has been discovered by many leading scientists that there exists a close relationship between bioelectricity and hypertension. Bioelectric stimulation may address two known root causes of hypertension (1) loss or arterial compliance and (2) in-balance of electrical potentials within the body. The PressureStim is designed to reduce loss of arterial compliance by controlled release of a number of growth factors that promote increased elasticity in the arteries including tropoelastin, SDF-1, VEGF, IGF-1, PDGF and HGF. A number of scientists propose the theory that during the hypertension prophase episode, there may appear abnormal movement for cell membrane ions, the pathological electric potentials. This electrical abnormality of blood vessel signal controls may then be followed by the phenomena of slowed blood flow, small artery spasms, and increased blood vessel compliance resistance, finally leading to the rise of blood pressure. The PressureStim bioelectric signals sequence for lowering blood pressure is designed to be applied to the body with its transmitted bioelectric signals intended to activate the bioelectric circuits in the body changing abnormal current flow patterns back to normal. It is designed to directly adjust the pathological electrical ionic membrane potentials, arterial muscle cells, and relieve the small artery spasm. The intent is also to strengthen red blood cell surface repulsion to reduce blood magnetic viscosity, and thus lower vessel and blood stream flow resistance. PressureStim is designed to additionally then lead continued regulation and integration in attempting to clear and dissolve cholesterol and neutral fat deposited on the tunica intima of arteries to remove stasis in the blood vessels. Thus, PressureStim is not only designed for acute decreases in blood pressure, but also to maintain a continuous effect for long term action in attempting to address the root causes of hypertension and thus many secondary to hypertension related cardiovascular diseases.
About PressureStim: PressureStim is a startup incubating in the Leonhardt’s Launchpads innovation accelerators in Santa Monica, CA and Salt Lake City, Utah with assistiance from Leonhardt’s Launchpads NorCal in Petaluma, CA.
About Leonhardt’s Launchpads: Founded by Leonhardt Ventures in 2008 Leonhardt’s Launchpads focuses on launching startups focused on Regenerative Medtech and Regenerative Economy innovations. 31 startups currently are within the Leonhardt’s Launchpads accelerators at three locations in Santa Monica, California, Petaluma, California and Salt Lake City, Utah. Leonhardt’s Launchpads 26 of the 31 startups are all based on Leonhardt Ventures patented technology platform of bioelectric stimulation controlled release of 15+ organ regeneration promoting proteins, including stem cell homing, proliferation and differentiation controls signals + a micro infusion pump re-filled daily with a fifteen component mixed stem cell + growth factors composition. Leonhardt’s Launchpads locations in California are operated by Cal-X Stars Business Accelerator, Inc. a California C corporation www.calxstars.com majority owned by Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures). Leonhardt’s Launchpads Utah, Inc. is a stand alone C corporation in Salt Lake City, Utah – http://leonhardtventures.com/leonhardts-launchpads-utah/ The business model of Leonhardt’s Launchpads is to advance startups through to first-in-man clinical data and then seek out a strategic specific organ focused partner.
About Leonhardt Ventures: Founded in 1982 by inventor Howard J. Leonhardt has led the development of a number of leading organ regeneration and recovery products including the world’s leading stent graft system for aortic aneurysm repair. Over 500,000 patients to date have been treated with Leonhardt inventions. See www.leonhardtventures.com for more information.
Cautionary Statement: Leonhardt’s Launchpads and Leonhardt Ventures specialize in early stage development of organ regeneration and recovery technologies with a very small staff and very small budget compared to competitors in the sector. The technologies are brand new and are unproven for safety and efficacy. By nature of this specialization the investment risk is very high and is not meant for “nest egg” savings and is reserved only for sophisticated accredited investors with experience in these type of investments. Some statements may be forward looking and information may change. Information on linked web sites may be outdated and is prone to errors to the small staff and budget to maintain their accuracy and updates. All of our patents are subject to upkeep with maintenance fees. All of our agreements with third parties are subject to conditions that must be met to keep them active and valid. If you have any questions requiring clarification of any information or updated information please contact us at the below email address or phone voice mail.